FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2004693107> ?p ?o ?g. }

• W2004693107 endingPage "e89974" @default.
• W2004693107 startingPage "e89974" @default.
• W2004693107 abstract "Background Increasingly, countries have introduced female vaccination against human papillomavirus (HPV), causally linked to several cancers and genital warts, but few have recommended vaccination of boys. Declining vaccine prices and strong evidence of vaccine impact on reducing HPV-related conditions in both women and men prompt countries to reevaluate whether HPV vaccination of boys is warranted. Methods A previously-published dynamic model of HPV transmission was empirically calibrated to Norway. Reductions in the incidence of HPV, including both direct and indirect benefits, were applied to a natural history model of cervical cancer, and to incidence-based models for other non-cervical HPV-related diseases. We calculated the health outcomes and costs of the different HPV-related conditions under a gender-neutral vaccination program compared to a female-only program. Results Vaccine price had a decisive impact on results. For example, assuming 71% coverage, high vaccine efficacy and a reasonable vaccine tender price of $75 per dose, we found vaccinating both girls and boys fell below a commonly cited cost-effectiveness threshold in Norway ($83,000/quality-adjusted life year (QALY) gained) when including vaccine benefit for all HPV-related diseases. However, at the current market price, including boys would not be considered ‘good value for money.’ For settings with a lower cost-effectiveness threshold ($30,000/QALY), it would not be considered cost-effective to expand the current program to include boys, unless the vaccine price was less than $36/dose. Increasing vaccination coverage to 90% among girls was more effective and less costly than the benefits achieved by vaccinating both genders with 71% coverage. Conclusions At the anticipated tender price, expanding the HPV vaccination program to boys may be cost-effective and may warrant a change in the current female-only vaccination policy in Norway. However, increasing coverage in girls is uniformly more effective and cost-effective than expanding vaccination coverage to boys and should be considered a priority." @default.
• W2004693107 created "2016-06-24" @default.
• W2004693107 creator A5010276379 @default.
• W2004693107 creator A5037563991 @default.
• W2004693107 creator A5056799177 @default.
• W2004693107 creator A5062122471 @default.
• W2004693107 creator A5075922755 @default.
• W2004693107 date "2014-03-20" @default.
• W2004693107 modified "2023-09-23" @default.
• W2004693107 title "Prevention of HPV-Related Cancers in Norway: Cost-Effectiveness of Expanding the HPV Vaccination Program to Include Pre-Adolescent Boys" @default.
• W2004693107 cites W1598581251 @default.
• W2004693107 cites W1963888311 @default.
• W2004693107 cites W1966468355 @default.
• W2004693107 cites W1975433270 @default.
• W2004693107 cites W1975501975 @default.
• W2004693107 cites W1979600349 @default.
• W2004693107 cites W2014164721 @default.
• W2004693107 cites W2019578856 @default.
• W2004693107 cites W2035499565 @default.
• W2004693107 cites W2045600910 @default.
• W2004693107 cites W2045893197 @default.
• W2004693107 cites W2054230937 @default.
• W2004693107 cites W2068606872 @default.
• W2004693107 cites W2069143946 @default.
• W2004693107 cites W2069536504 @default.
• W2004693107 cites W2078940177 @default.
• W2004693107 cites W2082352555 @default.
• W2004693107 cites W2087691406 @default.
• W2004693107 cites W2090504491 @default.
• W2004693107 cites W2101991638 @default.
• W2004693107 cites W2102786052 @default.
• W2004693107 cites W2105931327 @default.
• W2004693107 cites W2129363191 @default.
• W2004693107 cites W2130167819 @default.
• W2004693107 cites W2132896760 @default.
• W2004693107 cites W2137601145 @default.
• W2004693107 cites W2141226130 @default.
• W2004693107 cites W2145397804 @default.
• W2004693107 cites W2155310161 @default.
• W2004693107 cites W2155942218 @default.
• W2004693107 cites W2160524427 @default.
• W2004693107 cites W2165339119 @default.
• W2004693107 cites W4234032592 @default.
• W2004693107 doi "https://doi.org/10.1371/journal.pone.0089974" @default.
• W2004693107 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3961226" @default.
• W2004693107 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24651645" @default.
• W2004693107 hasPublicationYear "2014" @default.
• W2004693107 type Work @default.
• W2004693107 sameAs 2004693107 @default.
• W2004693107 citedByCount "81" @default.
• W2004693107 countsByYear W20046931072014 @default.
• W2004693107 countsByYear W20046931072015 @default.
• W2004693107 countsByYear W20046931072016 @default.
• W2004693107 countsByYear W20046931072017 @default.
• W2004693107 countsByYear W20046931072018 @default.
• W2004693107 countsByYear W20046931072019 @default.
• W2004693107 countsByYear W20046931072020 @default.
• W2004693107 countsByYear W20046931072021 @default.
• W2004693107 countsByYear W20046931072022 @default.
• W2004693107 countsByYear W20046931072023 @default.
• W2004693107 crossrefType "journal-article" @default.
• W2004693107 hasAuthorship W2004693107A5010276379 @default.
• W2004693107 hasAuthorship W2004693107A5037563991 @default.
• W2004693107 hasAuthorship W2004693107A5056799177 @default.
• W2004693107 hasAuthorship W2004693107A5062122471 @default.
• W2004693107 hasAuthorship W2004693107A5075922755 @default.
• W2004693107 hasBestOaLocation W20046931071 @default.
• W2004693107 hasConcept C112930515 @default.
• W2004693107 hasConcept C120665830 @default.
• W2004693107 hasConcept C121332964 @default.
• W2004693107 hasConcept C121608353 @default.
• W2004693107 hasConcept C126322002 @default.
• W2004693107 hasConcept C144024400 @default.
• W2004693107 hasConcept C149923435 @default.
• W2004693107 hasConcept C187212893 @default.
• W2004693107 hasConcept C203014093 @default.
• W2004693107 hasConcept C22070199 @default.
• W2004693107 hasConcept C2778220009 @default.
• W2004693107 hasConcept C2778308922 @default.
• W2004693107 hasConcept C2778580637 @default.
• W2004693107 hasConcept C2780441014 @default.
• W2004693107 hasConcept C29456083 @default.
• W2004693107 hasConcept C3019080777 @default.
• W2004693107 hasConcept C61511704 @default.
• W2004693107 hasConcept C71924100 @default.
• W2004693107 hasConcept C99454951 @default.
• W2004693107 hasConceptScore W2004693107C112930515 @default.
• W2004693107 hasConceptScore W2004693107C120665830 @default.
• W2004693107 hasConceptScore W2004693107C121332964 @default.
• W2004693107 hasConceptScore W2004693107C121608353 @default.
• W2004693107 hasConceptScore W2004693107C126322002 @default.
• W2004693107 hasConceptScore W2004693107C144024400 @default.
• W2004693107 hasConceptScore W2004693107C149923435 @default.
• W2004693107 hasConceptScore W2004693107C187212893 @default.
• W2004693107 hasConceptScore W2004693107C203014093 @default.
• W2004693107 hasConceptScore W2004693107C22070199 @default.
• W2004693107 hasConceptScore W2004693107C2778220009 @default.
• W2004693107 hasConceptScore W2004693107C2778308922 @default.

• next